Finding the relevance of antimicrobial stewardship for cystic fibrosis

J Cyst Fibros. 2020 Jul;19(4):511-520. doi: 10.1016/j.jcf.2020.02.012. Epub 2020 Feb 29.

Abstract

Antimicrobials have undoubtedly improved the lives of people with CF, but important antimicrobial-related toxicities and the emergence of antimicrobial-resistant bacteria associated with their use must be considered. Antimicrobial stewardship (AMS) is advocated across the spectrum of healthcare to promote the appropriate use of antimicrobials to preserve their current effectiveness and to optimise treatment, and it is clear that AMS strategies are applicable to and can benefit both non-CF and CF populations. This perspective explores the definition and components of an AMS program, the current evidence for AMS, and the reasons why AMS is a challenging concept in the provision of CF care. We also discuss the elements of CF care which align with AMS programs and principles and propose research priorities for AMS in CF.

Keywords: Antimicrobial stewardship; Antimicrobials; Pulmonary Exacerbations.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Anti-Bacterial Agents / pharmacology*
  • Antimicrobial Stewardship*
  • Cystic Fibrosis / drug therapy*
  • Humans

Substances

  • Anti-Bacterial Agents